Intervacc to participate at ABGSC Investor Day on September 7

On Monday, September 7, Intervacc’s CEO Andreas Andersson will participate in the live broadcast of ABGSC Investor Day in Stockholm. The company is in an exciting and intensive phase with, among other things, an ongoing process for a European granting of a Community marketing authorization for its first vaccine candidate Strangvac^®.

The ABGSC Investor Day is a livestreamed event that will be recorded and possible to watch later. Link to the livestream is provided below and the recording will be published on our website, on our Twitter channel @intervacc_se and at introduce.se.

ABGSC Investor Day is a quarterly recurring seminar, which provides an opportunity for investors to learn more about some of the companies covered by ABG Sundal Collier’s sponsored research (www.introduce.se). The presentation will be held in English.

About Intervacc
Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

About Strangvac^®
Strangvac^®, a modern vaccine against Strangles, a highly contagious and serious infection in horses caused by the bacterium Streptococcus equi. Strangvac^® consists of only soluble recombinant proteins, is injected intramuscularly and totally devoid of any living infectious agent. This results in a well-tolerated vaccine with excellent safety profile, as expected of a modern vaccine.